Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AB Science

< Previous 1 2 Next >
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
From AB Science
Via GlobeNewswire
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
From AB Science
Via GlobeNewswire
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
From AB Science
Via GlobeNewswire
AB Science announces a slight delay in the publication of its 2025 half-year financial report
From AB Science
Via GlobeNewswire
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
From AB Science
Via GlobeNewswire
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
From AB Science
Via GlobeNewswire
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
From AB Science
Via GlobeNewswire
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
From AB Science
Via GlobeNewswire
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
From AB Science
Via GlobeNewswire
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
From AB Science
Via GlobeNewswire
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
From AB Science
Via GlobeNewswire
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
From AB Science
Via GlobeNewswire
AB Science reports its revenues for the year 2024 and provides an update on its activities
From AB Science
Via GlobeNewswire
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
From AB Science
Via GlobeNewswire
AB Science will publish its 2024 annual financial report on May 9, 2025
From AB Science
Via GlobeNewswire
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
From AB Science
Via GlobeNewswire
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
From AB Science
Via GlobeNewswire
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
From AB Science
Via GlobeNewswire
AB Science today provides an update on its masitinib platform
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
From AB Science
Via GlobeNewswire
AB Science will participate in the Biomed Forum investors conference
From AB Science
Via GlobeNewswire
AB Science provides a summary of the webcast held on December 16, 2024
From AB Science
Via GlobeNewswire
AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
From AB Science
Via GlobeNewswire
AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
From AB Science
Via GlobeNewswire
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
From AB Science
Via GlobeNewswire
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
From AB Science
Via GlobeNewswire
AB Science announces a slight delay in the publication of its 2024 half-year financial report
From AB Science
Via GlobeNewswire
AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
From AB Science
Via GlobeNewswire
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
From AB Science
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.